Alfonso Tafur: Different Cancer Sites Drive Different Thrombotic Phenotypes
Alfonso Tafur, Vascular Medicine Fellowship Program Director at University of Chicago, Director of Vascular Medicine Department at NorthShore University, shared on LinkedIn:
”For years, many of us have treated cancer-associated thrombosis as if it were a single disease.
The data keep reminding us: it isn’t.
In the RIETE Registry, we looked at 18,000+ cancer patients vs. 88,000 without.
Within 90 days — 2.5× higher recurrent VTE, ~40% higher major bleeding.
But the real signal? Cancer site matters.
Lung and pancreatic drive clot risk. GI and GU drive bleeding risk.
Cancer-associated thrombosis is not one disease.
It is many biologically different thrombotic phenotypes.
Proud to be part of this team working toward precision vascular care.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Apr 16, 2026, 09:41Wolfgang Miesbach: Adeno-Associated Virus Neutralizing Antibodies and Their Clinical Impact on Gene Therapy
-
Apr 16, 2026, 09:33Jeyaraj Pandian: Low-Cost Stroke Rehabilitation Technologies at MENA-VINM 2026
-
Apr 16, 2026, 09:21Aurore Ughetto: The Hemocompatibility Burden of Micro-Axial Flow Pump Support
-
Apr 16, 2026, 09:09Naung Latt Htun: High Clinical Suspicion in Acquired Hemophilia A is Essential
-
Apr 16, 2026, 08:58Chittal Raulji: ASH-ISTH 2026 Guidelines for Anticoagulant Prophylaxis for Pediatric VTE Is Now Live in Blood Advances
-
Apr 16, 2026, 08:47Wolfgang Miesbach: Key Open Questions and Clinical Paradoxes in ITP
-
Apr 16, 2026, 08:19M Rafiqul Islam: Post-Thrombectomy Blood Pressure Management in Acute Ischemic Stroke
-
Apr 16, 2026, 06:58Rob Maloney: From Past to Progress in Hemophilia Care in the Dominican Republic
-
Apr 16, 2026, 06:51Michael Ertl: Patient-Reported Outcomes Reveal Differences in Perceived Stroke Recovery